Anixa Biosciences Stock Analysis
ANIX Stock | USD 3.30 0.01 0.30% |
Anixa Biosciences is undervalued with Real Value of 5.36 and Target Price of 12.0. The main objective of Anixa Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Anixa Biosciences is worth, separate from its market price. There are two main types of Anixa Biosciences' stock analysis: fundamental analysis and technical analysis.
The Anixa Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Anixa Biosciences is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Anixa Stock trading window is adjusted to America/New York timezone.
Anixa |
Anixa Stock Analysis Notes
About 17.0% of the company shares are held by institutions such as insurance companies. The book value of Anixa Biosciences was presently reported as 0.68. The company recorded a loss per share of 0.39. Anixa Biosciences had not issued any dividends in recent years. The entity had 1:25 split on the 26th of June 2015. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Anixa Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Anixa Biosciences please contact Amit Kumar at 408 708 9808 or go to https://www.anixa.com.Anixa Biosciences Investment Alerts
Anixa Biosciences had very high historical volatility over the last 90 days | |
The company reported the previous year's revenue of 210 K. Net Loss for the year was (9.93 M) with profit before overhead, payroll, taxes, and interest of 127.5 K. | |
Anixa Biosciences currently holds about 31.66 M in cash with (6.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
Anixa Biosciences has a frail financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial - Marketscreener.com |
Anixa Biosciences Upcoming and Recent Events
Earnings reports are used by Anixa Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
21st of March 2024 Upcoming Quarterly Report | View | |
12th of June 2024 Next Financial Report | View | |
31st of January 2024 Next Fiscal Quarter End | View | |
21st of January 2025 Next Fiscal Year End | View | |
31st of October 2023 Last Quarter Report | View | |
31st of October 2023 Last Financial Announcement | View |
Anixa Largest EPS Surprises
Earnings surprises can significantly impact Anixa Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-03-12 | 2024-01-31 | -0.09 | -0.1 | -0.01 | 11 | ||
2023-09-06 | 2023-07-31 | -0.09 | -0.08 | 0.01 | 11 | ||
2021-01-07 | 2020-10-31 | -0.1 | -0.09 | 0.01 | 10 |
Anixa Biosciences Environmental, Social, and Governance (ESG) Scores
Anixa Biosciences' ESG score is a quantitative measure that evaluates Anixa Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Anixa Biosciences' operations that may have significant financial implications and affect Anixa Biosciences' stock price as well as guide investors towards more socially responsible investments.
Anixa Stock Institutional Investors
Shares | Northern Trust Corp | 2024-09-30 | 71 K | Bank Of New York Mellon Corp | 2024-09-30 | 58.7 K | Corecap Advisors, Llc | 2024-09-30 | 44.8 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 44.5 K | Tyler-stone Wealth Management | 2024-09-30 | 42 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 41.1 K | International Assets Investment Management, Llc | 2024-09-30 | 37.8 K | Ci Private Wealth Llc | 2024-09-30 | 37.4 K | Gemmer Asset Management Llc | 2024-06-30 | 35 K | Vanguard Group Inc | 2024-09-30 | 1.4 M | Davidson D A & Co | 2024-09-30 | 671.1 K |
Anixa Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 106.51 M.Anixa Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.44) | (0.46) | |
Return On Capital Employed | (0.54) | (0.57) | |
Return On Assets | (0.44) | (0.46) | |
Return On Equity | (0.46) | (0.49) |
Management Efficiency
Anixa Biosciences has return on total asset (ROA) of (0.3465) % which means that it has lost $0.3465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5524) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 181.4 K in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.87 | 0.82 | |
Tangible Book Value Per Share | 0.87 | 1.73 | |
Enterprise Value Over EBITDA | (7.97) | (8.37) | |
Price Book Value Ratio | 4.63 | 4.39 | |
Enterprise Value Multiple | (7.97) | (8.37) | |
Price Fair Value | 4.63 | 4.39 | |
Enterprise Value | 134.1 M | 134.2 M |
The operational strategies employed by Anixa Biosciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.85 | Return On Assets (0.35) | Return On Equity (0.55) |
Technical Drivers
As of the 2nd of December, Anixa Biosciences shows the Mean Deviation of 2.62, downside deviation of 3.33, and Risk Adjusted Performance of 0.024. Anixa Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Anixa Biosciences Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Anixa Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Anixa Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Anixa Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anixa Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anixa Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anixa Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anixa Biosciences Outstanding Bonds
Anixa Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Anixa Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Anixa bonds can be classified according to their maturity, which is the date when Anixa Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
ANHEUSER BUSCH INBEV FIN Corp BondUS035242AN64 | View | |
ANHEUSER BUSCH INBEV FIN Corp BondUS035242AM81 | View | |
ANHEUSER BUSCH INBEV FIN Corp BondUS035242AB27 | View | |
US035229BP76 Corp BondUS035229BP76 | View | |
US035229BQ59 Corp BondUS035229BQ59 | View | |
ANHEUSER BUSCH PANIES LLC Corp BondUS03522AAJ97 | View |
Anixa Biosciences Predictive Daily Indicators
Anixa Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Anixa Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Anixa Biosciences Corporate Filings
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 23rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of September 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 1st of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 29th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 26th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 18th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Anixa Biosciences Forecast Models
Anixa Biosciences' time-series forecasting models are one of many Anixa Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Anixa Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Anixa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Anixa Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Anixa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Anixa Biosciences. By using and applying Anixa Stock analysis, traders can create a robust methodology for identifying Anixa entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (54.38) | (51.66) | |
Operating Profit Margin | (60.30) | (57.28) | |
Net Loss | (53.73) | (51.04) | |
Gross Profit Margin | 0.27 | 0.25 |
Current Anixa Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Anixa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Anixa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
12.0 | Strong Buy | 2 | Odds |
Most Anixa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Anixa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Anixa Biosciences, talking to its executives and customers, or listening to Anixa conference calls.
Anixa Stock Analysis Indicators
Anixa Biosciences stock analysis indicators help investors evaluate how Anixa Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Anixa Biosciences shares will generate the highest return on investment. By understating and applying Anixa Biosciences stock analysis, traders can identify Anixa Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 12.4 M | |
Common Stock Shares Outstanding | 31 M | |
Total Stockholder Equity | 24.3 M | |
Property Plant And Equipment Net | 166 K | |
Cash And Short Term Investments | 23.8 M | |
Cash | 915 K | |
Accounts Payable | 206 K | |
Net Debt | -740 K | |
50 Day M A | 3.2434 | |
Total Current Liabilities | 2 M | |
Other Operating Expenses | 11.2 M | |
Non Current Assets Total | 166 K | |
Stock Based Compensation | 4.4 M |
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.